Rocket Pharmaceuticals (RCKT) Amortization - Intangibles (2018 - 2026)

Rocket Pharmaceuticals has disclosed Amortization - Intangibles across 9 years of filings, most recently posting $1.2 million for Q1 2026.

• Amortization - Intangibles for Q1 2026 came in at $1.2 million, down 43.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (down 15.58% YoY), and the FY2025 annual result was $7.3 million, down 9.67% from the prior year.
• Amortization - Intangibles came in at $1.2 million for Q1 2026 at Rocket Pharmaceuticals, up from $1.2 million in the prior quarter.
• In the past five years, Amortization - Intangibles ranged from a high of $3.3 million in Q4 2023 to a low of -$577000.0 in Q1 2022.
• The 5-year median for Amortization - Intangibles is $1.8 million (2024), against an average of $1.6 million.
• Across the five-year window, Amortization - Intangibles surged 1560.9% in 2023 and sank 62.66% in 2024, its largest moves.
• Rocket Pharmaceuticals' Amortization - Intangibles stood at $1.1 million in 2022, then surged by 202.96% to $3.3 million in 2023, then tumbled by 62.66% to $1.2 million in 2024, then fell by 1.23% to $1.2 million in 2025, then grew by 1.74% to $1.2 million in 2026.
• The last three Amortization - Intangibles figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.